← Leaderboards
Serguei V Vinogradov
University Of Nebraska Medical Center
$4,193,151
Attributed
$5,112,923
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $590.6K · FY2005–15$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
Funding mix
By agency
NIH$5,112,923 · 5
By mechanism
R01$4,726,373 · 4
R21$386,550 · 1
Top collaborators
- Santhi Gorantla5 shared
Most similar at University Of Nebraska Medical Center
Same institution · by research overlap
- Alexander V Kabanov$28,176,125
- Tatiana K Bronich$14,219,791
- Aditya N Bade$2,497,932
- Benson Edagwa$6,144,379
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsNanogelIn VitroEncapsulatedPeptidesSurfaceBaseAdverse EffectsDesignNanoformulationCytotoxicityCell ModelMitochondriaToxic EffectBinding (Molecular Function)Drug TransportInnovationNanoDrug FormulationsIn VivoNucleoside AnalogNucleosidesCellsChemotherapy
Grant awards (20)
CNS Delivery of Activated Antiviral Drugs with Reduced Neurotoxicity (Nano-NRTIs)$371,250
R01 · FY2015 · NS · contact PI
CNS Delivery of Activated Antiviral Drugs with Reduced Neurotoxicity (Nano-NRTIs)$367,538
R01 · FY2014 · NS · contact PI
CNS Delivery of Activated Antiviral Drugs with Reduced Neurotoxicity (Nano-NRTIs)$358,256
R01 · FY2013 · NS · contact PI
Overcoming Drug Resistance to Nucleoside Analogs by Tumor-Targeted Active Nanofor$206,151
R01 · FY2013 · CA · contact PI
CNS Delivery of Activated Antiviral Drugs with Reduced Neurotoxicity (Nano-NRTIs)$371,250
R01 · FY2012 · NS · contact PI
Overcoming Drug Resistance to Nucleoside Analogs by Tumor-Targeted Active Nanofor$219,309
R01 · FY2012 · CA · contact PI
CNS Delivery of Activated Antiviral Drugs with Reduced Neurotoxicity (Nano-NRTIs)$371,250
R01 · FY2011 · NS · contact PI
Overcoming Drug Resistance to Nucleoside Analogs by Tumor-Targeted Active Nanofor$219,309
R01 · FY2011 · CA · contact PI
Overcoming Drug Resistance to Nucleoside Analogs by Tumor-Targeted Active Nanofor$226,091
R01 · FY2010 · CA · contact PI
Overcoming Drug Resistance to Nucleoside Analogs by Tumor-Targeted Active Nanofor$271,763
R01 · FY2009 · CA · contact PI
Nanodelivery of active NRTI to the central nervous system: humanized HIV murine m$185,625
R21 · FY2009 · NS · contact PI
Nanodelivery of active NRTI to the central nervous system: humanized HIV murine m$200,925
R21 · FY2008 · NS · contact PI
Bioengineering of the blood-brain barrier permeability$193,393
R01 · FY2008 · NS · contact PI
Polymer-Nucleotide Complexes with Cytotoxic Activity$219,528
R01 · FY2007 · CA · contact PI
Bioengineering of the blood-brain barrier permeability$193,393
R01 · FY2007 · NS · contact PI
Polymer-Nucleotide Complexes with Cytotoxic Activity$226,085
R01 · FY2006 · CA · contact PI
Bioengineering of the blood-brain barrier permeability$199,169
R01 · FY2006 · NS · contact PI
Polymer-Nucleotide Complexes with Cytotoxic Activity$254,025
R01 · FY2005 · CA
Bioengineering of the blood-brain barrier permeability$227,088
R01 · FY2005 · NS
Polymer-Nucleotide Complexes with Cytotoxic Activity$231,525
R01 · FY2004 · CA